Genedrive Regulatory News (GDR)

Company Epistem Plc

TIDM EHP.L (AIM)

Headline Pre-Close Trading Update

Released 22nd July: 7.00am UK

Epistem Holdings Plc

("Epistem" or "the Company")

Pre-Close Trading Update

Epistem (AIM: EHP), the personalised medicine and biotechnology company, today announces a pre-close trading statement for the year ended 30th June 2014.

Income over the full year remained solid and broadly in line with market expectations, with EBITDA losses expected to be around £2.5m reflecting the growing expenditure in preparation for launch of the Company's first product Genedrive®. Net cash at 30th June 2014 was £4.2m.

The Company expects to release its final results for the year ended 30th June 2014 on Tuesday 28th October 2014 and will hold an analysts' meeting on the day.

For further information contact:

Epistem Plc

Matthew Walls, Chief Executive Officer ++44 161 606 7258 John Rylands, Chief Financial Officer

Peel Hunt LLP

James Steel ++44 207 418 8900

Clare Terlouw

Walbrook PR

Mike Wort ++44 207 933 8780 Anna Dunphy

Notes for editors

Please see http://www.epistem.co.uk for additional information 

About Epistem:

Epistem is a personalised medicine and biotechnology company commercialising its expertise in adult stem cells in the areas of infectious and epithelial disease (oncology, gastrointestinal and dermatological). Epistem develops innovative diagnostics and biomarkers (Genedrive®), target discovery therapeutics and contract research services for drug development companies. Epistem operates three divisions, Personalised Medicine (Diagnostics and Biomarkers), Contract Research Services and Novel Therapies.